{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
alpha-tocopherol acetate
to a specific field?
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Proadifen is an inhibitor of drug metabolism and cytochrome P450 enzyme system activity. It stimulated the release of prostacyclin (PGI2) from the rabbit aorta, bovine aorta and human umbilical vein in vitro, but had no effect on cultured smooth muscle from the bovine aortic media. In human platelets, proadifen inhibited prostaglandin and thromboxane production induced by A23187, thrombin, and ADP. Proadifen might thus constitute the prototype of a new class of antiplatelet drugs.
Status:
Class (Stereo):
CHEMICAL (MIXED)
Droclidinium is the muscarinic receptors antagonist. It is an anticholinergic, spasmolytic agent.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Butaprost, a structural analog of PGE2, is a selective agonist for the EP2 receptor subtype. EP2 receptors are expressed on human neutrophils and on respiratory, vascular, and uterine smooth muscle. Butaprost binds with about 1/10 the affinity of PGE2 to the recombinant murine EP2 receptor and does not bind appreciably to the other murine EP receptors or the DP, TP, FP, and IP receptors. Butaprost has frequently been used to pharmacologically define the EP receptor expression profile of various human and animal tissues and cells. Butaprost effectively reduces the subconjunctival scarring response. Given the significance of wound healing modulation in blebs, butaprost's inhibitory effect on subconjunctival Tenon's fibroblasts may be beneficial in managing postoperative scarring in glaucoma surgery.
Status:
Investigational
Source:
NCT02179814: Not Applicable Interventional Suspended Bulimia Nervosa
(2012)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Racemetirosine is an orally active inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamine. At dosages of 600 to 3500mg daily, it is effective in controlling the hypertensive episodes and symptoms of catecholamine excess in phaeochromocytoma during preparation for surgery. Oral Racemetirosine is well absorbed and absorption appears constant in each individual over a wide dosage range. The drug is largely excreted via the kidneys, but extrarenal elimination has not been studied. Case reports on the clinical use of Racemetirosine in phaeochromocytoma indicate that the drug controls hypertension and symptoms of catecholamine excess in most patients during preparation for surgical removal of a tumor. In some cases, the addition of Racemetirosine to phenoxybenzamine plus propranolol has resulted in adequate control of symptoms previously unresponsive to the adrenergic blocking regimen. Drowsiness and sedation have been the most frequently reported side effects of Racemetirosine treatment.
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Class (Stereo):
CHEMICAL (ABSOLUTE)
Nicocodine is an opioid related to codeine. It is also an antitussive agent. Nicocodine exhibits at least twice the potency of codeine in clinical experiments. The study of the pharmacokinetic behaviour of nicocodine by means of blood and brain level curves of rats after i .v. application showed that the penetration of the blood
brain barrier seems to be favoured for nicocodine. The detected peak concentration of nicocodine in brain after i.v. application is 4.4 times higher than the blood level values at the same time - codeine the main metabolite is detected in almost equal amounts in brain and blood. A comparative assay of codeine and nicocodine after p.o. application of equimolar doses per kg body weight revealed that predominantly codeine is found in brain and its peak value after nicocodine administration is 3-fold higher than after codeine administration. Nicocodine is hydrolysable to morphine and the WHO Expert Committee on Addiction-Producing Drugs (1962) recommended its international control as a narcotic, like other convertible drugs in the morphine series.
Class (Stereo):
CHEMICAL (ACHIRAL)
FLUFOSAL is an antithrombotic agent.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Drobuline is a potent cardiac depressant (anti-arrhythmic) agent, which has been found to be effective against ventricular arrhythmias in dogs. This compound is a racemic mixture having a single center of optical activity. The two isomers of drobuline were found to be equally potent in converting cardiac arrhythmias in dogs after intravenous administration. The major route of biotransformation of drobuline in the dog was shown to be conjugation with glucuronic acid.
Class (Stereo):
CHEMICAL (ACHIRAL)
Oxabrexine was developed as a diuretic; however, this compound has never been marketed. Information about the current use of this compound is not available.
Status:
Investigational
Source:
NCT00065312: Phase 2 Interventional Completed Diabetes Mellitus, Non-Insulin-Dependent
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Naveglitazar is an oral dual peroxisome proliferator-activated receptor (PPAR) agonist, which was under development with Ligand Pharmaceuticals for the treatment of type 2 diabetes mellitus. Naveglitazar is a nonthiozolidinedione peroxisome proliferator-activated receptor (PPAR) α-γ dual, γ-dominant agonist that has shown glucose-lowering potential in animal models and in the clinic. Naveglitazar had been in phase II clinical trials for the once-daily oral treatment of type 2 diabetes, however, the development was discontinued.
